Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Heron Therapeutics (HRTX) Operating Expenses (2016 - 2025)

Historic Operating Expenses for Heron Therapeutics (HRTX) over the last 14 years, with Q3 2025 value amounting to $30.4 million.

  • Heron Therapeutics' Operating Expenses rose 928.44% to $30.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $113.0 million, marking a year-over-year decrease of 981.95%. This contributed to the annual value of $117.2 million for FY2024, which is 3209.95% down from last year.
  • As of Q3 2025, Heron Therapeutics' Operating Expenses stood at $30.4 million, which was up 928.44% from $29.0 million recorded in Q2 2025.
  • Heron Therapeutics' 5-year Operating Expenses high stood at $86.4 million for Q1 2022, and its period low was $26.4 million during Q4 2024.
  • Over the past 5 years, Heron Therapeutics' median Operating Expenses value was $38.2 million (recorded in 2023), while the average stood at $49.2 million.
  • Examining YoY changes over the last 5 years, Heron Therapeutics' Operating Expenses showed a top increase of 1975.27% in 2022 and a maximum decrease of 4911.04% in 2022.
  • Heron Therapeutics' Operating Expenses (Quarter) stood at $74.2 million in 2021, then plummeted by 49.11% to $37.8 million in 2022, then decreased by 8.44% to $34.6 million in 2023, then dropped by 23.69% to $26.4 million in 2024, then grew by 15.21% to $30.4 million in 2025.
  • Its last three reported values are $30.4 million in Q3 2025, $29.0 million for Q2 2025, and $27.3 million during Q1 2025.